Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors

Fibroblast growth factor receptors (FGFR) are emerging as an important therapeutic target for patients with advanced, refractory cancers. Most selective FGFR inhibitors under investigation show reversible binding, and their activity is limited by acquired drug resistance. This review summarizes the...

Descripción completa

Detalles Bibliográficos
Autores principales: Javle, Milind, King, Gentry, Spencer, Kristen, Borad, Mitesh J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Hepatobiliary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628593/
https://www.ncbi.nlm.nih.gov/pubmed/37390492
http://dx.doi.org/10.1093/oncolo/oyad149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628593/
https://www.ncbi.nlm.nih.gov/pubmed/37390492
http://dx.doi.org/10.1093/oncolo/oyad149

Ejemplares similares